Skip to main content
. 2016 Feb;101(2):226–234. doi: 10.3324/haematol.2015.133421

Figure 2.

Figure 2.

Serum concentrations of obinutuzumab and tumor sizes. (A) Inter-individual serum concentrations of obinutuzumab by tumor burden and dose group in patients with iNHL participating in phase II of GAUGUIN. (B) Inter-individual change in tumor size by dose group in patients with iNHL.